» Articles » PMID: 35814651

HIV Pre-exposure Prophylaxis and Its Impact on the Gut Microbiome in Men Having Sex With Men

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2022 Jul 11
PMID 35814651
Authors
Affiliations
Soon will be listed here.
Abstract

HIV/AIDS still imposes a high epidemiological and societal burden. Together with antiretroviral therapy, pre-exposure prophylaxis (PrEP) represents a fundamental tool in the fight against HIV/AIDS. PrEP is considered effective and safe, even though it may affect organs like the kidney, bone, and liver, as shown by randomized clinical trials (RCTs). These side effects may be mediated by alterations of the gut microbiome. Whilst the impact of the human rectal and vaginal microbiome on HIV prevention has been highly investigated among women, less is known about its effect among men having sex with men (MSM), a vulnerable population at high risk for HIV and disproportionately affected by HIV/AIDS. In the present paper, we will overview the effects of PrEP on the gut microbiota in MSM. Mining PubMed/MEDLINE, we identified three studies that have found significant changes affecting the gut microbiota. However, these shifts in the gut microbiome composition are variable, probably due to methodological differences, even though all studies reviewed in the present overview consistently report aberrations at the level of the gut microbiota. More data are needed, especially concerning the long-term side effects of PrEP: despite the studies included being a high-quality RCT, and two well-designed cross-sectional studies, evidence related to the impact of HIV PrEP on the gut microbiome in MSM is scarce and based on small populations. A better understanding of the interactions between the gut microbiota, sexual orientation/identity, and HIV prevention is expected to improve PrEP adherence and devise strategies to counteract PrEP-related side effects.

Citing Articles

Sexual behavior is linked to changes in gut microbiome and systemic inflammation that lead to HIV-1 infection in men who have sex with men.

Lin H, Chen Y, Abror-Lacks G, Price M, Morris A, Sun J Commun Biol. 2024; 7(1):1145.

PMID: 39277660 PMC: 11401892. DOI: 10.1038/s42003-024-06816-z.


The effect of sexual behavior on HIV-1 seroconversion is mediated by the gut microbiome and proinflammatory cytokines.

Lin H, Chen Y, Abror G, Price M, Morris A, Sun J Res Sq. 2024; .

PMID: 38343862 PMC: 10854284. DOI: 10.21203/rs.3.rs-3868545/v1.

References
1.
Delpino M, Quarleri J . Influence of HIV Infection and Antiretroviral Therapy on Bone Homeostasis. Front Endocrinol (Lausanne). 2020; 11:502. PMC: 7493215. DOI: 10.3389/fendo.2020.00502. View

2.
Ling Z, Jin C, Xie T, Cheng Y, Li L, Wu N . Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population. Sci Rep. 2016; 6:30673. PMC: 4967929. DOI: 10.1038/srep30673. View

3.
Spinner C, Boesecke C, Zink A, Jessen H, Stellbrink H, Rockstroh J . HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2015; 44(2):151-8. DOI: 10.1007/s15010-015-0850-2. View

4.
Dube M, Park S, Ross H, Love T, Morris S, Lee H . Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced Streptococcus and increased Erysipelotrichaceae in rectal microbiota. Sci Rep. 2018; 8(1):15212. PMC: 6185988. DOI: 10.1038/s41598-018-33524-6. View

5.
Hughes S, Levy C, Calienes F, Stekler J, Pandey U, Vojtech L . Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection. Cell Rep Med. 2020; 1(6):100096. PMC: 7511692. DOI: 10.1016/j.xcrm.2020.100096. View